Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Allison, Gaudy"'
Autor:
Fan Wu, Liangang Liu, Allison Gaudy, Xiaomin Wang, Leon Carayannopoulos, Michael Pourdehnad, Manisha Lamba
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 10, Pp 1473-1484 (2023)
Abstract Mezigdomide is a novel cereblon E3 ligase modulator (CELMoD) agent with enhanced autonomous cell‐killing activity in multiple myeloma (MM) cells, and promising immunomodulatory and antitumor activity in patients with MM. We developed a pop
Externí odkaz:
https://doaj.org/article/5d63ad4a03fa4278911b0cebdeda83b3
Autor:
Sandy W. Wong, Noffar Bar, María Victoria Mateos, Paz Ribas, Markus Hansson, Laura Paris, Craig Hofmeister, Paula Rodriguez-Otero, Maria Aranzazu Bermúdez, Armando Santoro, Andrew J. Yee, Maria Creignou, Cristina Encinas, Claudio Cerchione, Javier de la Rubia, Albert Oriol, Barbara Ferstl, Britta Besemer, Jinjie Chen, Alexander Chung, Isaac W. Boss, Allison Gaudy, Shaoyi LI, Kevin Hsu, Colin Godwin, Michael R. Burgess, Jesús San-Miguel, Luciano Jose Costa
Publikováno v:
HemaSphere, Vol 7, p e1220745 (2023)
Externí odkaz:
https://doaj.org/article/2230834f84a148e3a0a1059145ec090f
Autor:
Isaac Boss, Ethan Thompson, Allison Gaudy, Thi Minh Diem Vu, Colin Godwin, Michael Burgess, Sandy W. Wong, Luciano Costa
Publikováno v:
HemaSphere, Vol 7, p e77796ce (2023)
Externí odkaz:
https://doaj.org/article/f2c17c763e2d4aaba325c9c200fa161e
Autor:
Victoria P Werth, Richard A Furie, Ying Ye, Xiaojiang Zhan, Peter H Schafer, Nikolay Delev, Shimon Korish, Michael Weiswasser, Douglas R Hough, Allison Gaudy
Publikováno v:
Lupus Science and Medicine, Vol 9, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/42114d85d2d14912be0992652a48bf4b
Autor:
Yiming Cheng, Ying Ye, Allison Gaudy, Atalanta Ghosh, Yongjun Xue, Alice Wang, Simon Zhou, Yan Li
Publikováno v:
Clinical Pharmacology: Advances and Applications. 15:9-19
Yiming Cheng,1 Ying Ye,1 Allison Gaudy,1 Atalanta Ghosh,2 Yongjun Xue,3 Alice Wang,1 Simon Zhou,1 Yan Li1 1Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, NJ, USA; 2Global Biometrics and Data Sciences, Bristol Myers Squibb,
Autor:
Ying, Ye, Allison, Gaudy, Michael, Thomas, Josephine, Reyes, Barbara, Burkhardt, Gerald, Horan, Liangang, Liu, Jian, Chen, Atalanta, Ghosh, Leonidas N, Carayannopoulos, Daniel A, Tatosian, Maria, Palmisano
Publikováno v:
Clinical Pharmacology in Drug Development. 11:1394-1404
CC-90001 selectively inhibits c-Jun N-terminal kinase (JNK), a stress-activated protein implicated in fibrosis. In 3 phase 1 trials evaluating CC-90001 pharmacokinetics, pharmacodynamics, and safety, healthy adults (N = 184) received oral CC-90001 in
Autor:
Yiming Cheng, Allison Gaudy, Liangang Liu, Ying Ye, Michael Thomas, Yongjun Xue, Simon Zhou, Yan Li
Publikováno v:
Clinical Pharmacology in Drug Development.
Autor:
Sandy W. Wong, Noffar Bar, Laura Paris, Craig C Hofmeister, Markus Hansson, Armando Santoro, Maria-Victoria Mateos, Paula Rodríguez-Otero, Johan Lund, Cristina Encinas, Andrew J. Yee, Albert Oriol, Claudio Cerchione, Javier de la Rubia, Barbara Ferstl, Kristina Carlson, Paz Ribas, Arancha Bermúdez, Isaac W. Boss, Allison Gaudy, Shaoyi Li, Kevin Hsu, Colin D. Godwin, Michael R. Burgess, Jesús San-Miguel, Luciano J. Costa
Publikováno v:
Blood. 140:400-402
Publikováno v:
The Journal of Clinical Pharmacology. 60:67-74
A population pharmacokinetic (PPK) model to describe the pharmacokinetics of thalidomide in different patient populations was developed using data pooled from healthy subjects and patients with Hansen's disease, human immunodeficiency virus (HIV), an
Autor:
Noha Biserna, André Baruchel, Jan Starý, Daniel B. Lipka, Claudia Rossig, Concetta Micalizzi, Irith Baumann, Gérard Michel, Jennifer Poon, Allison Gaudy, Franco Locatelli, Thomas Klingebiel, Marry M. van den Heuvel-Eibrink, Christian Flotho, Daniel Menezes, Peter Nöllke, Bouchra Benettaib, Meera Patturajan, Susana Rives, Maximilian Schönung, Karsten Nysom, Markus Schmugge Liner, Mathew Simcock, Marco Zecca, Charlotte M. Niemeyer
Publikováno v:
blood advances
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
Blood Adv
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
Blood Adv
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for most children with juvenile myelomonocytic leukemia (JMML). Novel therapies controlling the disorder prior to HSCT are needed. We conducted a phase 2, multicen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93a538bf92eb9e760b7d3460e448e13c
https://hdl.handle.net/10807/229230
https://hdl.handle.net/10807/229230